Tekmira Pharmaceuticals completes offering of common shares

Tekmira Pharmaceuticals Corporation completed an offering of 7,500,000 common shares at a price of US$20.25 per share for gross proceeds of approximately US$151.9 million. Additionally, the underwriters were granted a 30-day option to purchase up to an additional 1,125,000 common shares which, if exercised, would result in additional gross proceeds.

Leerink Partners LLC and RBC Capital Markets, LLC acted as the lead book-runners for the offering. Nomura acted as a book-runner for the offering. Co-managers for the offering were: JMP Securities, Wedbush PacGrow and Lazard Frères & Co.

Tekmira was represented by Farris, Vaughan, Wills & Murphy LLP with a team led by Hector MacKay-Dunn and included Ronald Murray, Peter Roth and Matthew Smith (corporate/securities) and Thom Ciz (tax). Daniel Miller of Dorsey & Whitney LLP acted as Tekmira’s US counsel with a team including Daniel Nauth and Jenn Hu (corporate/securities) and John Hollinrake (tax).

Leerink Partners LLC and RBC Capital Markets, LLC were represented by Goodwin Procter LLP with a team led by Thomas Levato and included Alishba Kassim and Richard Torres (corporate/securities), Lindsay Wanner and Ashley Pantuliano (intellectual property) and Janet Andolina (tax).